The Rise of AI-Biotech: Why Hong Kong is the Next Breeding Ground for HealthTech Startups
Less than 15% of drug candidates make it from the laboratory to the market. Every stage between those two points asks your company to solve a different business challenge. One phase may call for funding, and the next could depend on clinical partners. Another may revolve around protecting your intellectual property before commercial discussions begin. But why do many AI-biotech founders continue to choose Hong Kong?
The jurisdiction you choose influences many of those decisions. A strong research environment gives you easier access to talent, funding, laboratories, and industry partners as your priorities change. Hong Kong startup ecosystem gives you all that, putting you closer to the people and resources you’ll eventually need.
How Insilico Medicine Put Hong Kong on the AI-Biotech Map?
Building a biotech startup means your next milestone depends on how quickly you can move from an idea to a drug candidate, which typically takes around 3-6years. Insilico Medicine reached that point in under 18 months for one of its AI-powered programmes and advanced it to Phase I clinical trials in under 30 months.
Insilico Medicine is a biotechnology company with its international headquarters based at Hong Kong Science and Technology Parks Corporation (HKSTP). It built Pharma.AI that helps researchers identify disease targets, design potential drug molecules, predict how those molecules could behave, and select the strongest candidates for laboratory testing.
Pharma.AI brings together multiple AI models including:
- PandaOmics for target discovery
- Chemistry42 for molecular design, and
- InClinico for predicting the probability of success in clinical trials.
The company is also developing its own pipeline of drug candidates across oncology, fibrosis, metabolic diseases, and solid tumors. It also continues discovering new therapeutic programmes using its AI platform.
Hong Kong has given that work a place to grow. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, said:“Hong Kong is one of the best places on the planet to live, conduct cutting-edge research, and do business”. Source
It has also entered into collaborations with global pharma companies including Sanofi, Fosun Pharma, Menarini Group, Exelixis and Eli Lilly. In 2025, Eli Lilly expanded its collaboration with Insilico Medicine in a deal valued up to US$2.75 billion in potential milestone payments and royalties.
If you’re deciding where to build your AI biotech startup, Insilico Medicine makes a strong case for why Hong Kong works. Every milestone the company reached adds another reason to keep the city on your shortlist.
What Do Hong Kong Universities and Government Grants Offer HealthTech Founders?
Every stage in your business requires different people, new expertise, and fresh funding to keep your progress going. Hong Kong’s universities and grant opportunities provide that too.
Talent from HKU and CUHK
Doing business in Hong Kong gives you a steady pipeline of researchers, clinicians, and engineers through The University of Hong Kong (HKU) and The Chinese University of Hong Kong (CUHK).
Both universities are already investing in artificial intelligence, robotics, precision medicine, and biomedical research. This eventually gives graduates and researchers who can become part of your founding team or early research hires.
They also have Technology Transfer Offices that manage intellectual property, licensing, collaborative agreements, and industry partnerships, making it easier for you to turn new ideas into commercial products.
All about government grants
Hong Kong provides multiple grants for university researchers and startup founders. Here are a few of them:
TSSSU: If you’re building your AI-biotech startup around research from HKU or CUHK, you could qualify for support through the Technology Start-up Support Scheme for Universities (TSSSU).
| TSSSU@HKU | TSSSU@CUHK | |
|---|---|---|
| Funding | Up to HK$1.5 million per year under TSSSU-O or TSSSU+ for up to 3 years. | TSSSU-O: up to HK$600,000/year. TSSSU+: up to HK$1 million/year in matching funds, each for up to 3 years. |
| Beyond funding | One-year iDendron membership, HKU TEA (Qianhai Base) Grant Matching Opportunity (up to CNY 1 million), networking and public exposure opportunities. | Access to HKSTP Incubation Programme (subject to eligibility), potential investors, industry partners, and entrepreneurship mentoring through CUHK’s Knowledge Transfer Office. |
| Best suited for | If you’re building around research developed at HKU and want funding plus commercialization support. | If you’re commercializing CUHK technology and want mentoring, investor connections, incubation opportunities, and funding. |
InnoHK: If your work depends on collaboration, InnoHK connects you with leading universities and research institutions worldwide. Through its clusters such as Health@InnoHK and AIR@InnoHK, you can work alongside established research teams while developing healthcare technologies, artificial intelligence, and robotics for commercial use.
Enterprise Support Scheme (ESS): As your AI-biotech startup grows, the Enterprise Support Scheme (ESS) can help fund your research and development projects. If you’re already conducting in-house R&D in Hong Kong, you can apply for support year-round. It provides up to $10 million per project.
Beyond government grants
As your company grows, private investment becomes equally important. HKSTP Venture Fund directly invests in technology startups from seed to pre-IPO stage and co-invests with private investors. Since its launch, the HK$1 billion fund has helped startups raise additional private capital through its investor network and investment matching programme.
Hong Kong also gives a dedicated listing route for pre-revenue biotech companies under HKEX Chapter 18A. This means clinical-stage companies can raise capital before generating revenue. As of January 2026, 84 biotech companies have collectively raised more than US$17.5 billion through the regime.
Startupr expert says:“Based on our experience helping technology companies establish in Hong Kong, many AI-biotech founders focus on building the technology first. Commercial conversations usually begin much earlier. Pharmaceutical companies, research partners, and investors often look at how your company owns its intellectual property, who controls it, and whether it’s ready for licensing long before a product reaches the market. Preparing those basics early makes those conversations much easier.”
Why Does the Greater Bay Area Matter for AI-Biotech Startups?
Every AI-biotech company will need wet laboratories, specialist equipment, manufacturing partners, regulatory support, or clinical collaborators, depending on what you’re building. Hong Kong provides many of those capabilities through GBA, IP protection, and HKSTP initiatives.
Protect your intellectual property in Hong Kong
If your AI-biotech startup develops a new technology, Hong Kong lets you apply for an Original Grant Patent (OGP) directly through its own patent system. The city also offers a 5% concessionary tax rate on eligible profits earned from qualifying intellectual property through its Patent Box regime.
Expand your research into Shenzhen
As your research grows, HKSTP’s Shenzhen Branch gives you a base inside Shenzhen’s Futian District, around 1.2 kilometers from Futian Port. The site includes wet laboratories, dry laboratories, independent offices, co-working space, and meeting facilities, helping you work with research teams and technology partners in both Hong Kong and Shenzhen.
Use the Greater Bay Area as one innovation network
The Greater Bay Area combines 11 cities with a population of more than 88 million. This allows you to widen your search beyond Hong Kong, and as your company progresses, thereby also expanding the possibilities of research partners, manufacturing, specialized suppliers, hospitals and future clients.
Its connection also reaches clinical research. Through the Greater Bay Area Clinical Trial Collaboration Platform, you can submit a single service request for your clinical trial.
The platform then matches you with suitable research institutions, hospitals, and investigators across the region based on your project’s needs. It also gives you access to expert support in clinical trial design, statistics, regulatory affairs, and ethics review.
Your Technology Needs the Right Home
The science behind your company may be unique, but building the business around it follows a familiar pattern. Every stage introduces new decisions, new collaborators, and new opportunities. Hong Kong gives you a place to grow through each of those stages, from research and funding to clinical collaboration and commercialization.
If you’re ready to establish your company in this city, Startupr covers all the essential guidance.
Contact our experts to learn more.
–